Selected research
Market Structure
Global Repurposed Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Repurposed Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Repurposed Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Repurposed Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Repurposed Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Repurposed Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Repurposed Drugs include Teva, Johnson & Johnson, Novartis, Mylan, Pfizer, GSK, R-Pharma, Glenmark and Fujifilm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Repurposed Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Repurposed Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Repurposed Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Repurposed Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Repurposed Drugs Segment by Company
Teva
Johnson & Johnson
Novartis
Mylan
Pfizer
GSK
R-Pharma
Glenmark
Fujifilm
Dr. Reddy
ChemRar Group
Bausch Health
Repurposed Drugs Segment by Type
Generic Drugs
Clinical Trial Failed Drugs
Repurposed Drugs Segment by Application
Cardiovascular Diseases
Mental Illness
Cancer
Other
Repurposed Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Repurposed Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Repurposed Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Repurposed Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Repurposed Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Repurposed Drugs industry.
Chapter 3: Detailed analysis of Repurposed Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Repurposed Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Generic Drugs
- Clinical Trial Failed Drugs
Applications
- Cardiovascular Diseases
- Mental Illness
- Cancer
- Other
Companies covered
- Teva
- Johnson & Johnson
- Novartis
- Mylan
- Pfizer
- GSK
- R-Pharma
- Glenmark
- Fujifilm
- Dr. Reddy
- ChemRar Group
- Bausch Health
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Repurposed Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Generic Drugs
- 1.2.3 Clinical Trial Failed Drugs
- 1.3 Market Analysis by Application
- 1.3.1 Global Repurposed Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Cardiovascular Diseases
- 1.3.3 Mental Illness
- 1.3.4 Cancer
- 1.3.5 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Repurposed Drugs Growth Trends by Region
- 1.5.1 Global Repurposed Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Repurposed Drugs Market Size by Region (2021-2026)
- 1.5.3 Repurposed Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Repurposed Drugs Market Dynamics
- 2.1 Repurposed Drugs Industry Trends
- 2.2 Repurposed Drugs Industry Drivers
- 2.3 Repurposed Drugs Industry Opportunities and Challenges
- 2.4 Repurposed Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Repurposed Drugs Revenue by Company (2021-2026)
- 3.2 Global Repurposed Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Repurposed Drugs Key Company Head office and Area Served
- 3.4 Global Repurposed Drugs Company, Product Type & Application
- 3.5 Global Repurposed Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Repurposed Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Repurposed Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Repurposed Drugs Tier 1, Tier 2, and Tier 3
4 Repurposed Drugs Market by Type
- 4.1 Global Repurposed Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Repurposed Drugs Market Size by Type (2021-2032)
- 4.3 Global Repurposed Drugs Market Size Share by Type (2021-2032)
5 Repurposed Drugs Market by Application
- 5.1 Global Repurposed Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Repurposed Drugs Market Size by Application (2021-2032)
- 5.3 Global Repurposed Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Teva
- 6.1.1 Teva Company Information
- 6.1.2 Teva Business Overview
- 6.1.3 Teva Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Teva Repurposed Drugs Product Portfolio
- 6.1.5 Teva Recent Developments
- 6.2 Johnson & Johnson
- 6.2.1 Johnson & Johnson Company Information
- 6.2.2 Johnson & Johnson Business Overview
- 6.2.3 Johnson & Johnson Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Johnson & Johnson Repurposed Drugs Product Portfolio
- 6.2.5 Johnson & Johnson Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Novartis Repurposed Drugs Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Mylan
- 6.4.1 Mylan Company Information
- 6.4.2 Mylan Business Overview
- 6.4.3 Mylan Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Mylan Repurposed Drugs Product Portfolio
- 6.4.5 Mylan Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Pfizer Repurposed Drugs Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 GSK
- 6.6.1 GSK Company Information
- 6.6.2 GSK Business Overview
- 6.6.3 GSK Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 GSK Repurposed Drugs Product Portfolio
- 6.6.5 GSK Recent Developments
- 6.7 R-Pharma
- 6.7.1 R-Pharma Company Information
- 6.7.2 R-Pharma Business Overview
- 6.7.3 R-Pharma Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 R-Pharma Repurposed Drugs Product Portfolio
- 6.7.5 R-Pharma Recent Developments
- 6.8 Glenmark
- 6.8.1 Glenmark Company Information
- 6.8.2 Glenmark Business Overview
- 6.8.3 Glenmark Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Glenmark Repurposed Drugs Product Portfolio
- 6.8.5 Glenmark Recent Developments
- 6.9 Fujifilm
- 6.9.1 Fujifilm Company Information
- 6.9.2 Fujifilm Business Overview
- 6.9.3 Fujifilm Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Fujifilm Repurposed Drugs Product Portfolio
- 6.9.5 Fujifilm Recent Developments
- 6.10 Dr. Reddy
- 6.10.1 Dr. Reddy Company Information
- 6.10.2 Dr. Reddy Business Overview
- 6.10.3 Dr. Reddy Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Dr. Reddy Repurposed Drugs Product Portfolio
- 6.10.5 Dr. Reddy Recent Developments
- 6.11 ChemRar Group
- 6.11.1 ChemRar Group Company Information
- 6.11.2 ChemRar Group Business Overview
- 6.11.3 ChemRar Group Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 ChemRar Group Repurposed Drugs Product Portfolio
- 6.11.5 ChemRar Group Recent Developments
- 6.12 Bausch Health
- 6.12.1 Bausch Health Company Information
- 6.12.2 Bausch Health Business Overview
- 6.12.3 Bausch Health Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Bausch Health Repurposed Drugs Product Portfolio
- 6.12.5 Bausch Health Recent Developments
7 North America
- 7.1 North America Repurposed Drugs Market Size (2021-2032)
- 7.2 North America Repurposed Drugs Market Size by Type
- 7.2.1 North America Repurposed Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Repurposed Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Repurposed Drugs Market Share by Type (2021-2032)
- 7.3 North America Repurposed Drugs Market Size by Application
- 7.3.1 North America Repurposed Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Repurposed Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Repurposed Drugs Market Share by Application (2021-2032)
- 7.4 North America Repurposed Drugs Market Size by Country
- 7.4.1 North America Repurposed Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Repurposed Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Repurposed Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Repurposed Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Repurposed Drugs Market Size (2021-2032)
- 8.2 Europe Repurposed Drugs Market Size by Type
- 8.2.1 Europe Repurposed Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Repurposed Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Repurposed Drugs Market Share by Type (2021-2032)
- 8.3 Europe Repurposed Drugs Market Size by Application
- 8.3.1 Europe Repurposed Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Repurposed Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Repurposed Drugs Market Share by Application (2021-2032)
- 8.4 Europe Repurposed Drugs Market Size by Country
- 8.4.1 Europe Repurposed Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Repurposed Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Repurposed Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Repurposed Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Repurposed Drugs Market Size (2021-2032)
- 9.2 China Repurposed Drugs Market Size by Type
- 9.2.1 China Repurposed Drugs Market Size by Type (2021-2026)
- 9.2.2 China Repurposed Drugs Market Size by Type (2027-2032)
- 9.2.3 China Repurposed Drugs Market Share by Type (2021-2032)
- 9.3 China Repurposed Drugs Market Size by Application
- 9.3.1 China Repurposed Drugs Market Size by Application (2021-2026)
- 9.3.2 China Repurposed Drugs Market Size by Application (2027-2032)
- 9.3.3 China Repurposed Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Repurposed Drugs Market Size (2021-2032)
- 10.2 Asia Repurposed Drugs Market Size by Type
- 10.2.1 Asia Repurposed Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Repurposed Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Repurposed Drugs Market Share by Type (2021-2032)
- 10.3 Asia Repurposed Drugs Market Size by Application
- 10.3.1 Asia Repurposed Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Repurposed Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Repurposed Drugs Market Share by Application (2021-2032)
- 10.4 Asia Repurposed Drugs Market Size by Country
- 10.4.1 Asia Repurposed Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Repurposed Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Repurposed Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Repurposed Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Repurposed Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Repurposed Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Repurposed Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Repurposed Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Repurposed Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Repurposed Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Repurposed Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Repurposed Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Repurposed Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Repurposed Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Repurposed Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Repurposed Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Repurposed Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Repurposed Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst